At Atlas Antibodies, we don’t just make antibodies.
We build confidence into every experiment.
Our Triple A Polyclonals™ and PrecisA Monoclonals™ are precision-designed antibodies developed in close collaboration with the Human Protein Atlas project and validated on real human tissues, across a range of cancers and normal organs.
Whether you work in oncology, neuroscience, pathology, or basic research our antibodies provide the depth, consistency, and validation you need. Each antibody is connected to extensive expression profiles, tissue-level staining, and subcellular localization data through the Human Protein Atlas — with complete transparency.
Generated using unique, recombinant PrEST antigens, designed for maximum specificity and minimal cross-reactivity.
Every antibody is validated using standardized IHC protocols on over 40 normal and cancer tissues.
A vast amount of our antibodies go through enhanced validation, as an extra step of antibody validation.
Each product is linked to full expression and performance data in the Human Protein Atlas.
Each antibody is validated using IHC and WB, with careful tissue and lysate selection based on literature to ensure specific and reliable performance.
Functional characterization is performed on a large number of ELISA-positive cell supernatants to select the optimal clones for each application. Selected hybridomas are then subcloned and expanded.
All PrecisA Monoclonal antibodies are isotyped to allow multiplexing with isotype-specific secondary antibodies.
PrecisA Monoclonals are epitope-mapped using synthetic overlapping peptides in a bead-based array format. This ensures the selection of clones with non-overlapping epitopes.
Discover how researchers used a novel patient-derived 3D cell model and an Atlas Antibodies' anti-ATRX antibody to uncover new insights into how IDH-mutant gliomas turn malignant, opening doors for new therapeutic targets.
Read more
